---
document_datetime: 2023-09-21 20:40:00
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/fiasp-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: fiasp-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.2876915
conversion_datetime: 2025-12-28 09:38:43.523499
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Fiasp

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                |
|----------------------|------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------|
| R/0028               | Renewal of the marketing authorisation.                                                              | 24/06/2021                          | 18/08/2021                                  | SmPC, Labelling and PL           | Renewal of the marketing authorisation |
| WS/2056              | This was an application for a variation following a worksharing procedure according to Article 20 of | 10/06/2021                          | n/a                                         |                                  |                                        |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | Commission Regulation (EC) No 1234/2008. B.II.c.3.a.2 - Change in source of an excipient or reagent with TSE risk - From TSE risk material to vegetable or synthetic origin - For excipients or reagents USED in the manufacture of a biol/immunol AS or in a biol/immunol medicinal product   |            |            |                                  |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| PSUSA/1749/ 202009 | Periodic Safety Update EU Single assessment - insulin aspart                                                                                                                                                                                                                                   | 06/05/2021 | n/a        |                                  | PRAC Recommendation - maintenance |
| WS/1997            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                            | 11/03/2021 | n/a        |                                  |                                   |
| IAIN/0027          | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                             | 19/02/2021 | n/a        |                                  |                                   |
| WS/1901            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                   | 24/09/2020 | 18/08/2021 | SmPC, Annex II, Labelling and PL |                                   |
| IB/0023            | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a                                                                                                                                                                                              | 17/04/2020 | n/a        |                                  |                                   |

<div style=\"page-break-after: always\"></div>

|                    | biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |                        |                                                                                                                                                                                                                                                                                                        |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1749/ 201909 | Periodic Safety Update EU Single assessment - insulin aspart                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 17/04/2020 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                      |
| IB/0022            | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 30/03/2020 | n/a        |                        |                                                                                                                                                                                                                                                                                                        |
| II/0018/G          | This was an application for a group of variations. The SmPC sections 1, 2, 3, 4.2, 4.4, 6.3, 6.4, 6.5 and 6.6 of the SmPC have been updated to include information on the new 1.6 ml PumpCart cartridge. Please refer to Attachment 1 which includes all approved changes to the Product Information. The Labelling and PL have been updated accordingly. B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes | 12/03/2020 | 30/09/2020 | SmPC, Labelling and PL | The SmPC sections 1, 2, 3, 4.2, 4.4, 6.3, 6.4, 6.5 and 6.6 of the SmPC have been updated to include information on the new 1.6 ml PumpCart cartridge. Please refer to Attachment 1 which includes all approved changes to the Product Information. The Labelling and PL have been updated accordingly. |
| IAIN/0021          | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 11/02/2020 | n/a        |                        |                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| IA/0019   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 06/12/2019   | n/a        |                           |                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1687   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 05/12/2019   | n/a        |                           |                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0016   | Update of the SmPC section 4.8 with data from an updated safety pool, further to assessment of the last PSUR assessment for insulin aspart (EMEA/H/C/PSUSA/00001749/201809). This update is based on 3 efficacy and safety studies: NN1218-3852 (52 week) - a study of Fiasp compared to insulin aspart both in combination with insulin detemir in adults with Type 1 Diabetes; NN1218-3854 a study of Continuous Subcutaneous Insulin Infusion of Fiasp compared to NovoRapid in adults with Type 1 Diabetes; NN1218-4131 a study of Fiasp compared to NovoRapid both in combination with insulin degludec in adults with Type 1 Diabetes. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 19/09/2019   | 30/09/2020 | SmPC, Labelling and PL    | The SmPC section 4.8 has been updated with new frequencies for allergic reactions, lipodystrophy and injection site/ infusion site reactions in the section 'Description of selected adverse reactions'. Data on Infusion site reaction adverse events in the population on CSII (i.e. study 3854 and 3931) has been presented separately. Please refer to the SmPC for further details. The Labelling and PL have been updated accordingly. |
| II/0010   | Extension of Indication to include treatment of children and adolescents aged 1 year and above                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 27/06/2019   | 31/07/2019 | SmPC, Annex II, Labelling | Please refer to Scientific Discussion Fiasp-H-C-4046-II-10                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                    | based on data from the phase 3b clinical trial NN1218-4101, supported by data from the Clinical Pharmacology trials NN1218-4371 and clinical study NN1218-3888 which was included in the initial MAA. As a consequence, sections 4.1, 4.2, 4.8, and 5.1 of the SmPC and the corresponding sections of the Package Leaflet are updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to make other non- related minor or editorial changes were implemented throughout the EU PI to increase readability/consistency. An updated RMP version 3.1 was agreed during the procedure. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   |            |            | and PL   |                                                                                                                                                                                                                                                                                                                                                                                                      |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1092            | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 12/07/2019 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                      |
| PSUSA/1749/ 201809 | Periodic Safety Update EU Single assessment - insulin aspart                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 26/04/2019 | 01/07/2019 |          | Based on the post-marketing data submitted within this PSUR, the PRAC concludes that anaphylactic reactions should be added to section 4.8 of the SmPC for Fiasp, in line with the SmPC for NovoRapid and NovoMix. Following 7 new reported cases of medically confirmed systemic allergic reactions for Fiasp and the already established evidence suggesting a causal relationship between insulin |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                            |            |            |                        | aspart and anaphylactic reactions, the updates to the section 4.8 of SmPC for Fiasp are justified.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------|
| IB/0014   | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                                                                                                                                    | 29/06/2019 | 31/07/2019 | SmPC, Labelling and PL |                                                                                                      |
| IB/0013   | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                               | 15/05/2019 | n/a        |                        |                                                                                                      |
| IB/0012   | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                               | 26/04/2019 | n/a        |                        |                                                                                                      |
| WS/1564   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 04/04/2019 | n/a        |                        |                                                                                                      |
| IG/1038   | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                             | 14/01/2019 | n/a        |                        |                                                                                                      |
| IAIN/0007 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging                                                                                                                                                                                                                                                              | 12/10/2018 | n/a        |                        |                                                                                                      |

<div style=\"page-break-after: always\"></div>

|                    | site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1405            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 19/07/2018 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| PSUSA/1749/ 201709 | Periodic Safety Update EU Single assessment - insulin aspart                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 12/04/2018 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0003/G          | This was an application for a group of variations. Update of the RMP to upgrade the risk of mix-up between basal and bolus insulin from a potential to an important identified risk (RMP version 2.1); in addition, to update the secondary packaging material design and change colour of selected plastic components from yellow to red, consequently section 4.2 of the SmPC is being updated to no longer include the word 'yellow' due to the new proposed colour coding of Fiasp. The PL has been updated accordingly. A communication to Health Care Professionals and Patients regarding similarity of Fiasp and Tresiba products that are currently on the market has been agreed. B.II.e.6.a - Change in any part of the (primary) packaging material not in contact with the finished | 09/03/2018 | 12/04/2018 | SmPC and PL | To mitigate the risk of medication errors due to mix up between Fiasp and Tresiba, the MAH has proposed 2 new risk minimisation measures (RMMs): (1) introduction of new colour coding for Fiasp and (2) use of educational materials as part of a communication strategy prior to the new colours being implemented. The proposed new colour coding for Fiasp comprise changes from yellow with a white contrast to yellow with a red contrast on the labels and cartons and from yellow to red for plastic components for the prefilled pens. As a result of this group of variations, section 4.2 of the SmPC is being updated to no longer include the word 'yellow' due to the new proposed colour coding of Fiasp: 'FlexTouch is colour coded yellow and accompanied by a package leaflet with detailed instructions for use to be followed'. The PL has been updated accordingly. The risk management plan (RMP) has been updated accordingly to provide background information on the |

<div style=\"page-break-after: always\"></div>

|           | product formulation - Change that affects the product information C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                  |            |            |                                  | medication errors, upgrading of the safety concern of 'Medication errors (mainly wrong drug administered)' from an important potential risk to an important identified risk, details of the colour coding changes and details of the proposed communications. The targeted questionnaire to follow up reports of medication errors has been additionally updated. Changes unrelated to medication errors, mainly concerning extent of use of the product, have also been made to the RMP.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0005   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                       | 19/03/2018 | 25/02/2019 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| WS/1132   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.e.2 - Introduction of a post approval change management protocol related to the AS | 05/05/2017 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IAIN/0001 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                   | 16/02/2017 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |